D.Phil., CSO, Jounce Therapeutics
Debbie Law joined Jounce Therapeutics, a Cambridge-based biotech focused on cancer immunotherapy, as chief scientific officer in January of 2015. Prior to this, Debbie served as Vice President of Immunology, Oncology and Immunomodulators at Merck working on programs including pembrolizumab and MK-4166 (anti-GITR). She has over 20 years of experience in biologics drug development in the fields of oncology and immunology has held positions including VP of Biologics Discovery (Merck); CSO for Ablynxn.v. and VP of Research at PDL Biopharma. Debbie received her B.Sc. in Immunology from Glasgow University and her D. Phil. in Immunology from Oxford University prior to pursuing post-doctoral research at UCSF in San Francisco.
Developing JTX-2011 ICOS Agonist: A Translational Approach
JTX-2011 is currently under evaluation in the clinic for the treatment of solid tumors. This talk will discuss preclinical data supporting a dual mechanism of action for JTX-2011 and describe how these data, together with our translational approach, are helping to identify potential biomarkers that inform our clinical development strategy.
Session Abstract – PMWC 2017 Silicon Valley
Session Synopsis: Immunotherapy is considered a game-changer and holds a lot of promise. This session will provide some background on immunotherapy, discuss whether over time immunotherapy will become the standard-of-care for most cancers, what long term cure rates are being achieved, the important role of combination therapy and some of the newer immunotherapy applications and therapies.